Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-02

Study Completion Date

2021-10-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This phase 1, multicenter, dose-escalation study is designed to find the Recommended Phase 2 Dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory CLL/SLL and to assess the clinical activity of the combination with rituximab in patients with relapsed or refractory CLL/SLL and to assess the clinical activity of the combination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukemia CLL Relapsed CLL Refractory Chronic Lymphocytic Leukemia Relapsed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma SLL Relapsed Small Lymphocytic Lymphoma Refractory Small Lymphocytic Lymphoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

venetoclax idelalisib rituximab

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Patients will start on dose level 1 of venetoclax in combination with rituximab and idelalisib, then escalate or de-escalate (if lower dose is available) based upon the estimated probabilities of toxicity from an extension of the continual reassessment method for 2 agents.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

150 mg BID of idelalisib + 100 mg QD of venetoclax

150 mg BID of idelalisib + 100 mg QD of venetoclax

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age ≥ 18 years of age. Relapsed or refractory B-cell CLL or biopsy-proven SLL. Treatment required in the opinion of the investigator

Must have had at least one standard treatment with a regimen containing at least one of the following agents/classes of agents; and where specified, must also meet the treatment duration, progression, and/or relapse criteria for that class of agent:

* Fludarabine
* An alkylator (eg, chlorambucil, bendamustine)
* A BTK inhibitor (eg, ibrutinib, acalabrutinib); and must have progressed or relapsed \> 6 months after last BTK inhibitor treatment
* An anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab)
* A BCL-2-family protein inhibitor (eg, venetoclax, navitoclax); and

* if best response is \< CR with BCL-2-family protein inhibitor treatment
* must have had ≥ 1 year of BCL-2-family protein inhibitor treatment; and
* must have progressed \> 6 months after last BCL-2-family protein inhibitor treatment
* if best response is CR with BCL-2-family protein inhibitor treatment
* must have relapsed ≥ 1 year after last BCL-2-family protein inhibitor treatment
* A PI3K inhibitor (eg, idelalisib, duvelisib, TGR-1202, copanlisib, buparlisib); and must have progressed or relapsed \> 6 months after last treatment with the PI3K inhibitor (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION)

Prior allogeneic stem cell transplant allowed provided the following criteria are met:

* ≥ 12 months have elapsed since allogeneic transplant
* No current or prior evidence of graft-versus-host disease
* No current requirement for immunosuppressive therapy Prior autologous stem cell transplant allowed provided ≥ 6 months have elapsed since autologous transplant.

Eastern Cooperative Oncology Group performance status of 0, 1, or 2

Adequate bone marrow function as follows:

* Absolute neutrophil count (ANC) ≥ 1,000/mm3 (without support of granulocyte colony stimulating factors)
* Platelets ≥ 50,000/mm3 (untransfused)
* Hemoglobin ≥ 9.0 g/dL

Adequate coagulation, renal, and hepatic function as follows:

* aPTT and PT ≤ 1.2 × upper limit of normal (ULN) for the laboratory
* Calculated creatinine clearance ≥ 50 mL/min as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine, and gender
* AST and ALT ≤ 1.5 × ULN for the laboratory
* Bilirubin ≤ 1.5 × ULN for the laboratory. For a woman of childbearing potential (WCBP), a negative serum pregnancy test performed within 7 days prior to initiation of study treatment.

Note: Postmenopausal is defined as any of the following:

* Age ≥ 60 years
* Age \< 60 years and amenorrheic for at least 1 year with follicle-stimulating hormone (FSH) and plasma estradiol levels in the postmenopausal range
* Bilateral oophorectomy WCBP and male patients must agree to use a medically accepted form of birth control for the duration of study treatment and for at least 1 month following completion of venetoclax and/or idelalisib or 12 months following rituximab, whichever occurs later.

Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Known histologic transformation from CLL/SLL to an aggressive lymphoma (ie, Richter's transformation).

Known history of drug-induced pneumonitis History of inflammatory bowel disease. Central nervous system involvement Clinically significant infection including active hepatitis B or hepatitis C requiring active treatment, or active CMV infection Known human immunodeficiency virus (HIV) seropositivity. \* Note: HIV testing is not required.

Vaccination within 4 weeks prior to initiation of rituximab \*Note: Review vaccination status. Patients should, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines at least 4 weeks prior to initiating rituximab.•Ongoing requirement for warfarin (due to potential drug-drug interactions that may increase the exposure of warfarin and ensuing complications).

Has received any of the following within 14 days prior to initiation of study treatment:(NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION)

* Anti-cancer therapy
* Investigational therapy Has not recovered to ≤ grade 1 toxicity(s) from prior therapy, except for chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of the study regimen (eg, alopecia). (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION) Has not recovered to ≤ grade 1 toxicity(s) from idelalisib and rituximab, except for chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of the study regimen (eg, alopecia). (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 1ST-STEP REGISTRATION)

Ongoing or planned treatment with any of the following:

* Steroid therapy for anti-neoplastic intent
* Strong or moderate CYP3A inhibitor or inducer, and/or a narrow-therapeutic sensitive substrate
* P-gp inhibitor or narrow-therapeutic sensitive P-gp substrate If any of these agents have been used, patients must be off them for ≥ 1 week before initiation of study treatment.

Prior intolerance to any component of study regimen that, in the opinion of the investigator would preclude study treatment.

A cardiovascular disability status of New York Heart Association Class ≥ II Diagnosis or treatment for another malignancy within 1 year of study registration, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy Active liver disease other than lymphoid involvement, inflammatory bowel disease, or Crohn's disease Malabsorption syndrome or other condition that precludes enteral route of administration.

Exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

* Uncontrolled infection (viral, bacterial, or fungal)
* Grade 3 or greater neutropenic fever within 1 week prior to initiation of study treatment Active autoimmune cytopenias (for 2 or more weeks), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura.

Pregnancy or breastfeeding Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk, interfere with the patient's participation in the study or hinder evaluation of study results

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Victor Y Yazbek, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Massey Cancer Center

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2018-01661

Identifier Type: OTHER

Identifier Source: secondary_id

MCC-15-12310

Identifier Type: -

Identifier Source: org_study_id

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Dose Combination 1-1

Dose combination 1-1

Dose Combination 1-2

dose combination 1-2

Dose Combination 1-3

Dose combination 1-3

Dose Combination 1-4

dose combination 1-4

Sub-Trial Dose Combination 2-1

Sub-Trial: Dose combination 2-1

Sub-Trial Dose Combination 2-2

Sub-Trial: Dose combination 2-2

Interventions